The bispecific antibody and BiTE market is witnessing robust growth driven by advances in immuno-oncology and rising demand for targeted canc ...

Barclays (LON: BARC) has initiated coverage on Galderma Group AG (SIX: GALD) and Zealand Pharma (NASDAQ: ZEAL) with Overweight ratings, citing distinct growth dri ...

While the broader European market is up mid-single digits year-to-date, the SXDP pharma index has underperformed, losing more ...

Both well-established and small, clinical-stage pharma companies are investing heavily to be able to someday compete with ...

For high-risk patients with type 2 diabetes, oral semaglutide reduced risk for major cardiovascular and ischemic limb-related ...

"Rising liver disease cases and biotech innovations are fueling demand for advanced therapies, with personalized medicine and fibrosis-targeting treatments shaping the global market landscape." BOSTON ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Roche Holding AG (RHHVF – Research Report) and Alkermes (ALKS – Research Report). Confident I ...

“Steven brings a unique 360-degree perspective on global drug development gained from a career at major pharma companies, CROs and the FDA,” said Adam Steensberg, Chief Executive Officer, Zealand ...

Company announcement – No. 12 / 2025 Zealand Pharma announces closing of collaboration and license agreement with Roche Copenhagen, Denmark, May 9, 2025 – Zealand Pharma A/S ("the Company" or ...

Company announcement – No. 12 / 2025 Zealand Pharma announces closing of collaboration and license agreement with Roche Copenhagen, Denmark, May 9, 2025 – Zealand Pharma A/S ("the Company" or ...

Zealand Pharma is optimistic about its future, expecting the closure of the Roche deal in Q2 2025. Analysts share this optimism, with a strong buy consensus and price targets ranging from $110 to ...